Performance so far
Monsanto (MON) is set to release its fiscal 2Q16 quarter earnings on April 6, 2016. YTD (year-to-date), Monsanto has returned -8.9%, with the stock closing at $90.10 on March 24, 2016. The broader portfolio of the Materials Select Sector SPDR ETF (XLB) has returned 1.7%, while S&P 500 index has returned negative 1.3% over the same period.
On the other hand, Syngenta (SYT) has returned 2.5% YTD, whereas E I du Pont de Nemours and Company (DD) has returned -4.6%, and Dow Chemicals (DOW) is also in the negative territory, with a return of -0.2% YTD.
Monsanto is one of the leading global agribusiness companies. It provides biotech seeds, herbicides, biotechnology traits, and precision agriculture products that aim to improve yields and lower costs for farmers. Monsanto has a presence in more than 150 countries and reaches its end customers (farmers, garden professionals, and consumers) through independent retailers, distributors, dealers, agents, and agricultural cooperatives. The company has two segments:
- Seeds and Genomics
- Agricultural Productivity
With Monsanto’s 2Q16 earnings release around the corner, we’ll discuss its earnings expectation in this series. We’ll also look at estimates for sales, EBITDA, and earnings per share. We’ll discuss analyst ratings as well as price targets for the next 12-months, and after the earnings release, of course, we’ll publish a full review of how these ratings and targets have changed (if at all) after the fact.
Let’s start with Monsanto’s sales.